Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,465 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines.
Takahashi K, Inukai T, Imamura T, Yano M, Tomoyasu C, Lucas DM, Nemoto A, Sato H, Huang M, Abe M, Kagami K, Shinohara T, Watanabe A, Somazu S, Oshiro H, Akahane K, Goi K, Kikuchi J, Furukawa Y, Goto H, Minegishi M, Iwamoto S, Sugita K. Takahashi K, et al. Among authors: sugita k. PLoS One. 2017 Dec 13;12(12):e0188680. doi: 10.1371/journal.pone.0188680. eCollection 2017. PLoS One. 2017. PMID: 29236701 Free PMC article.
Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.
Huang M, Inukai T, Miyake K, Tanaka Y, Kagami K, Abe M, Goto H, Minegishi M, Iwamoto S, Sugihara E, Watanabe A, Somazu S, Shinohara T, Oshiro H, Akahane K, Goi K, Sugita K. Huang M, et al. Among authors: sugita k. Cancer Med. 2018 Apr;7(4):1297-1316. doi: 10.1002/cam4.1323. Epub 2018 Feb 23. Cancer Med. 2018. PMID: 29473342 Free PMC article.
Resistance of t(17;19)-acute lymphoblastic leukemia cell lines to multiagents in induction therapy.
Watanabe A, Inukai T, Kagami K, Abe M, Takagi M, Fukushima T, Fukushima H, Nanmoku T, Terui K, Ito T, Toki T, Ito E, Fujimura J, Goto H, Endo M, Look T, Kamps M, Minegishi M, Takita J, Inaba T, Takahashi H, Ohara A, Harama D, Shinohara T, Somazu S, Oshiro H, Akahane K, Goi K, Sugita K. Watanabe A, et al. Among authors: sugita k. Cancer Med. 2019 Sep;8(11):5274-5288. doi: 10.1002/cam4.2356. Epub 2019 Jul 15. Cancer Med. 2019. PMID: 31305009 Free PMC article.
Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19).
Hirose K, Inukai T, Kikuchi J, Furukawa Y, Ikawa T, Kawamoto H, Oram SH, Göttgens B, Kiyokawa N, Miyagawa Y, Okita H, Akahane K, Zhang X, Kuroda I, Honna H, Kagami K, Goi K, Kurosawa H, Look AT, Matsui H, Inaba T, Sugita K. Hirose K, et al. Among authors: sugita k. Blood. 2010 Aug 12;116(6):962-70. doi: 10.1182/blood-2009-09-244673. Epub 2010 Jun 2. Blood. 2010. PMID: 20519628 Free article.
Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
Nemoto A, Saida S, Kato I, Kikuchi J, Furukawa Y, Maeda Y, Akahane K, Honna-Oshiro H, Goi K, Kagami K, Kimura S, Sato Y, Okabe S, Niwa A, Watanabe K, Nakahata T, Heike T, Sugita K, Inukai T. Nemoto A, et al. Among authors: sugita k. Mol Cancer Ther. 2016 Jan;15(1):94-105. doi: 10.1158/1535-7163.MCT-14-1065. Epub 2015 Dec 4. Mol Cancer Ther. 2016. PMID: 26637365
1,465 results